Search Results

Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress.

Vivet Therapeutics and Pfizer Inc. announced that they have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare and potentially life-threatening liver disorder.

- Mirum expands potential opportunities across rare disease pipeline - Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Vivet Therapeutics today announced that new data regarding VTX-803, Vivet’s AAV-based gene therapy in development for the treatment of PFIC3, will be presented during the ASGCT 24th Annual Meeting, May 11 - 14, 2021.

Vivet Therapeutics announced that both the Food and Drug Administration and the European Commission have granted Orphan Drug Designation for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3.

The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.